Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Nektar Therapeutics (NKTR)

24.025   -0.405 (-1.66%) 07-10 16:00
Open: 24.28 Pre. Close: 24.43
High: 24.53 Low: 23.88
Volume: 509,821 Market Cap: 4,276M
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 24.555 - 24.689 24.689 - 24.801
Low: 23.555 - 23.722 23.722 - 23.861
Close: 23.768 - 24.023 24.023 - 24.235

Technical analysis

as of: 2020-07-10 4:30:36 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 29.27     One year: 34.19
Support: Support1: 21.82    Support2: 19.81
Resistance: Resistance1: 25.06    Resistance2: 29.27
Pivot: 23.32
Moving Average: MA(5): 24.27     MA(20): 22.80
MA(100): 20.42     MA(250): 20.85
MACD: MACD(12,26): 0.69     Signal(9): 0.54
Stochastic oscillator: %K(14,3): 82.67     %D(3): 87.80
RSI: RSI(14): 59.80
52-week: High: 33.50  Low: 13.63  Change(%): -27.7
Average Vol(K): 3-Month: 117788  10-Days: 97092

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
NKTR has closed below upper band by 28.4%. Bollinger Bands are 17% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 09 Jul 2020
Should You Review Recent Insider Transactions At Nektar Therapeutics (NASDAQ:NKTR)? - Simply Wall St

Wed, 08 Jul 2020
Nektar Therapeutics (NKTR) Soars 2.65% on July 08 - Equities.com

Wed, 08 Jul 2020
Should You Buy Nektar Therapeutics (NKTR) in Biotechnology Industry? - InvestorsObserver

Tue, 07 Jul 2020
Does the Market Like Nektar Therapeutics (NKTR) Stock After it Has Risen 8.79% in a Week? - InvestorsObserver

Mon, 06 Jul 2020
Nektar Therapeutics (NKTR) Soars 1.96% on July 06 - Equities.com

Thu, 02 Jul 2020
Nektar Therapeutics (NKTR): Share Tumbled 6.16% last week: What Happened? - The News Heater

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 178
Shares Float (M) 176
% Held by Insiders 1.17
% Held by Institutions 99.49
Shares Short (K) 27,700
Shares Short P. Month (K) 27,730

Stock Financials

EPS -2.620
EPS Est This Year -0.980
EPS Est Next Year -1.100
Book Value (p.s.) 7.290
Profit Margin
Operating Margin -297.73
Return on Assets (ttm) -12.6
Return on Equity (ttm) -31.4
Qtrly Rev. Growth 79.2
Gross Profit (p.s.) 0.524
Sales Per Share 0.770
EBITDA (p.s.) -2.209
Qtrly Earnings Growth
Operating Cash Flow (M) -326
Levered Free Cash Flow (M) -165

Stock Valuations

PE Ratio -9.17
PEG Ratio
Price to Book value 3.30
Price to Sales 31.22
Price to Cash Flow -13.12

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.